基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02616 基石药业-B

未开盘 10-15 16:08:35

4.695

-0.085

-1.78%

最高4.815	最低4.635	成交量749.50万
今开4.800	昨收4.780	日振幅3.77%
总市值74.93亿	流通市值74.93亿	总股本15.96亿
成交额3,523万	换手率0.47%	流通股本15.96亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"基石药业-B","latestPrice":4.695,"timestamp":1792051715007,"preClose":4.78,"halted":0,"volume":7495000,"delay":0,"changeRate":-0.01778242677824267,"floatShares":1596000000,"shares":1596000000,"eps":-0.314752,"marketStatus":"未开盘","change":-0.085,"latestTime":"10-15 16:08:35","open":4.8,"high":4.815,"low":4.635,"amount":35232640,"amplitude":0.037657,"askPrice":4.695,"askSize":3000,"bidPrice":4.685,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.302,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792114200000},"marketStatusCode":0,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":4.78,"openAndCloseTimeList":[[1792027800000,1792036800000],[1792040400000,1792051200000]],"volumeRatio":0.8662077572239708,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616","defaultTab":"news","newsList":[{"id":"2675376082","title":"【券商聚焦】中信建投：AI重塑药物研发 2035年全球市场有望破460亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675376082","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675376082?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:00","pubTimestamp":1792026019,"startTime":"0","endTime":"0","summary":"AI深度介入靶点识别、分子设计等药物研发环节，破解传统制药高投入、长周期难题。报告测算，全球AI制药市场2025年规模约24.9亿美元，2035年有望突破460亿美元，CAGR超33%，国内市场具备高增长潜力；科技巨头、药企、CXO等多方入局，海内外多家头部企业完成平台搭建与商业化验证。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993729","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2778985437.USD","LU0516423174.USD","02616","KURE","LU1152091754.HKD","06185","01177","02269","ARTY","LU0029874061.USD","BK1141","KCE","LU0348825331.USD","IBBJ","01877","IE00BZ08YS42.EUR","SG9999002562.SGD","QTOC","LU0501845795.SGD","BK1500","09995","06160","AIPO","BK1576","LU0128522744.USD","LU0051755006.USD","09688","01801","LU0052750758.USD","LU0456846285.SGD","LU0456827905.SGD","01093","CHAT","02142","LU0979878070.USD","09926","LU0326950275.SGD","IE00B031HY20.USD","LU0516422440.USD","LU1008478684.HKD","LU2242644610.SGD","LU0516422952.EUR","VTHR","LU0588546209.SGD","AGIX","601066","BK1588","LU0128526141.USD","LU1251922891.USD","LU0856984785.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120424983","title":"基石药业-B公布9月股份变动月报 新增7,381股","url":"https://stock-news.laohu8.com/highlight/detail?id=1120424983","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120424983?lang=zh_cn&edition=full","pubTime":"2026-10-07 16:37","pubTimestamp":1791362241,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年10月7日披露了截至2026年9月30日的证券变动月报。2026年9月期间，公司因行使“2019年1月30日采纳并于2023年3月7日修订及重列的首次公开发售后雇员持股计划”而新增发行7,381股普通股。截至本月底，已发行股份总数增加至1,596,330,953股，库存股份仍为0股。公司确认，当月内不存在股份购回、注销或转让自库藏等活动。截至本月末，基石药业-B的公众持股量已符合适用的最低要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673792787","title":"【券商聚焦】国金证券：行业有望迎业绩与估值戴维斯双击，创新药板块底部配置价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2673792787","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673792787?lang=zh_cn&edition=full","pubTime":"2026-10-05 08:50","pubTimestamp":1791161445,"startTime":"0","endTime":"0","summary":"随着后续管线商业化兑现、全球创新价值链话语权提升，行业有望迎来业绩与估值的戴维斯双击，创新药板块底部配置价值凸显。中国研究占全体大会核心LBA总量的1/3，这标志着中国肿瘤创新研发已深度融入全球研发体系，成为驱动全球肿瘤诊疗升级的重要力量，持续利好国内创新药企国际化发展与临床价值兑现。2026 ESMO已公布LBA标题，29项LBA的试验药物由中国药企原研或参与开发，涉及约20家企业，其中5项进入主席研讨会。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992996","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","BK1610","HK0000165453.HKD","LU1807302812.USD","01801","LU0244354667.USD","LU0516422952.EUR","01177","09688","09926","01093","BK1583","LU0314109678.HKD","02142","LU0540923850.HKD","MEDX","LU1242518931.SGD","BK1576","IE0008368742.USD","LU0823426480.USD","IE00BPRC5H50.USD","LNGR","LU1794554557.SGD","06160","02616","LU0043850808.USD","LU2399975544.HKD","LU0823426308.USD","IBBQ","LU1328277881.USD","LU0052750758.USD","LU1226287875.USD","159992","01877","LU1226288253.USD","LU2242644610.SGD","KURE","09995","600109","BK0201","02269","06978","KCE","LU0315179316.USD","LU0359202008.SGD","LU0455707207.USD","BK1161","BK1515","LU0856984785.SGD","LU0211977185.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671956822","title":"港股异动 | 基石药业-B(02616)涨近7% ESMO数据更新在即 高管持续增持彰显发展信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2671956822","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671956822?lang=zh_cn&edition=full","pubTime":"2026-09-29 14:02","pubTimestamp":1790661761,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B涨近7%，截至发稿，涨6.81%，报5.49港元，成交额3518.91万港元。此外，公司首席执行官、研发总裁及执行董事杨建新于9月17日至22日以个人资金在公开市场上合共购买49.6万股公司股份，总代价逾270万港元。据悉，自2022年8月担任首席执行官以来，杨建新博士已于公开市场累计购买超1421万股公司股份。此次股份购买充分彰显杨博士对公司的长期承诺以及对公司未来业务前景的坚定信心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","VXUS","02616","BK1161","BK1574","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127868216","title":"基石药业-B 2026年中期营收2.05亿元，经调整净亏损2.31亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127868216","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127868216?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:37","pubTimestamp":1790602666,"startTime":"0","endTime":"0","summary":"基石药业-B公布2026年上半年业绩，报告期内公司实现收入2.05亿元，较上年同期的0.49亿元增长约315.2%。该收入主要由药品销售、授权费及特许权使用费构成，其中药品销售额1.83亿元，授权费收入0.07亿元，特许权使用费收入0.15亿元。非国际财务报告准则下，经扣除以股份为基础的付款费用后，期内净亏损从上年同期的2.65亿元收窄至2.31亿元，亏损额减少0.34亿元。经营活动现金流出为2.22亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"基石药业-B 2026年中期营收2.05亿元，经调整净亏损2.31亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192849572","title":"基石药业-B：CEO杨建新博士再斥资逾270万港元增持49.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1192849572","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192849572?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:36","pubTimestamp":1790246181,"startTime":"0","endTime":"0","summary":"基石药业-B9月24日公告称，公司首席执行官、研发总裁兼执行董事杨建新博士于2026年9月17日至22日期间，动用个人资金在公开市场合计增持公司股份496,000股，总代价逾270万港元。公告显示，自2022年8月出任首席执行官以来，杨建新博士已在公开市场累计购入14,210,500股公司股份。公司董事会表示，本次增持体现了杨建新博士对基石药业长期承诺及对未来业务前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669464619","title":"基石药业-B(02616)获首席执行官兼执行董事杨建新增持合共49.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669464619","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669464619?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:33","pubTimestamp":1790245989,"startTime":"0","endTime":"0","summary":"本公司董事会认为，股份购买事项充分体现杨博士对本公司的长期承诺以及对本公司未来业务前景的坚定信心。自2022年8月担任首席执行官以来，杨博士已于公开市场累计购入合共1421.05万股股份。紧随股份购买事项后，杨博士持有合共相当于本公司于本公告日期的已发行股本总额约5.31%的股份。杨博士不排除于适当时候进一步增持本公司股份的可能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500610.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669430903","title":"【券商聚焦】国金证券：中国双抗/ADC/小核酸具全球竞争力，有望催化创新药新一轮出海与估值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2669430903","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669430903?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:05","pubTimestamp":1790211910,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指，2026 WCLC首尔召开，中国创新药密集登场：康方依沃西一线NSCLC头对头优效帕博利珠，PD-1/VEGF双抗领跑IO2.0；翰森/宜联B7-H3ADC进全体会场，ADC向前线+围手术期迁移；KRAS G12D、HER2、EGFR耐药等精准治疗破局。中国双抗/ADC/小核酸具全球竞争力，数据国际领先，有望催化创新药新一轮出海与估值重估。风险提示：新药研发失败风险；研发进度低于预期风险；药品降价风险。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992369","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","LU2097828805.USD","MEDX","SG9999002562.SGD","LU2039709279.SGD","LU1226288253.USD","600109","LU1770034418.SGD","LU0314109678.HKD","LU0029874061.USD","LU0320764599.SGD","LU2476274720.SGD","LU0128526141.USD","IE00B5MMRT66.SGD","01093","IBBQ","LU0348784397.USD","LU1993786604.SGD","09995","LU0348735423.USD","01877","LU1719994722.HKD","02269","LU1251922891.USD","LU0516423091.SGD","BK1515","06185","159992","LU0708995583.HKD","KCE","02616","02142","HK0000165453.HKD","LU0359202008.SGD","06160","09688","LU1152091168.USD","LU0828237510.HKD","LU1152091754.HKD","LU0039217434.USD","KURE","LU0348766576.USD","LU0315179316.USD","LU0417516902.SGD","LNGR","09926","LU1226287792.SGD","01801","LU3063872942.SGD","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668996177","title":"执行董事兼首席执行官杨建新增持基石药业-B(02616)13.25万股 每股作价约5.24港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668996177","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668996177?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:26","pubTimestamp":1789644373,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月17日，执行董事兼首席执行官杨建新增持基石药业-B13.25万股，每股作价5.2361港元，总金额约为69.38万港元。增持后最新持股数目约为8441.66万股，最新持股比例为5.29%。补充资料：Purchase of shares by Dr. Yang in the open market using his personal funds. Box 28: These shares represent the Restricted Share Units and Share Options that have been granted or are to be issued to Dr. Yang under the Pre-IPO RSU Scheme, the Pre-IPO Share Option Scheme, and the Post-IPO Incentive Schemes.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","BK1161","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156279184","title":"基石药业-B：Jianxin Yang增持，好仓比例升至5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156279184","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156279184?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:32","pubTimestamp":1789637521,"startTime":"0","endTime":"0","summary":"Jianxin Yang于2026年9月17日在联交所场内以每股均价5.2361港元买入基石药业-B（02616）股份13.25万股，涉资约69.38万港元，属场内主动交易，即在二级市场直接买卖股份。Jianxin Yang此次增持前持有基石药业-B好仓8428.41万股，占比5.28%；增持后持股量为8441.66万股，好仓比例升至5.29%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666128556","title":"【券商聚焦】中信证券：中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666128556","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666128556?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:59","pubTimestamp":1789001960,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年以来，中国创新药国内市场快速放量，从中报来看头部创新药企业在新产品驱动下，创新药收入快速增长，biopharma陆续进入盈利拐点；出海创新药开始进入三期/注册研究兑现阶段；近期多个国际学术大会将至，众多创新药管线进入密集的数据催化期。该机构认为中国创新药进入全球价值兑现阶段，建议关注：①头部国际化创新药企业有望迎来产品全球价值兑现期；②头部创新药企业产品放量进入新的成长阶段；③具有全球潜力的管线资产国际化有望加速兑现。综上，我们维持创新药行业“强于大市”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991210","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","LU0348825331.USD","LU0516422952.EUR","LU0181495838.USD","LU0463099449.HKD","LU1655091616.SGD","LU1720050803.USD","LU0819121731.USD","02616","LU0979878070.USD","01177","KURE","LU0561508036.HKD","SG9999004220.SGD","02142","01801","09926","01093","06030","LU1580142542.USD","LU0417516738.SGD","IE00B543WZ88.USD","BK0028","LU1226287792.SGD","LU2148510915.USD","LU0405327494.USD","LU1820825898.SGD","06185","LU1226287875.USD","LU2039709279.SGD","LU0348783233.USD","LU1813983027.USD","600030","01877","LU0572944931.SGD","LU1969619763.USD","LU2580892862.HKD","09995","BK1161","02269","LU1997245177.USD","LU1794554557.SGD","06160","LU1880383366.USD","KCE","LU1064130708.USD","LU1961090484.USD","IE0008369823.USD","LU1255011170.USD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665426603","title":"港股异动 | 基石药业-B(02616)午后涨超6% 获纳入港股通标的证券名单 国际大行相继看好公司发展前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2665426603","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665426603?lang=zh_cn&edition=full","pubTime":"2026-09-08 13:41","pubTimestamp":1788846117,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B午后涨超6%，截至发稿，涨5.27%，报6.385港元，成交额8209.73万港元。消息面上，基石药业-B发布公告，本公司发行并于香港联合交易所有限公司上市的股份获纳入港股通标的证券名单，自2026年9月7日起生效。其中，高盛预计，未来6至12个月将是基石药业关键催化剂密集兑现的阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","KCAI","FLHK","BK1161","161027","02616","VXUS","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398386","title":"基石药业-B(02616.HK)获纳入港股通标的证券名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398386","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398386?lang=zh_cn&edition=full","pubTime":"2026-09-07 08:32","pubTimestamp":1788741157,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665338398","title":"基石药业-B(02616.HK)：公司获纳入港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2665338398","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665338398?lang=zh_cn&edition=full","pubTime":"2026-09-07 08:27","pubTimestamp":1788740821,"startTime":"0","endTime":"0","summary":"格隆汇9月7日丨基石药业-B(02616.HK)发布公告，公司发行并于香港联交所上市的股份获纳入港股通标的证券名单，自2026年9月7日起生效。\r\n\r\n　　基石药业首席执行官、研发总裁及执行董事杨建新博士表示：“本次成功获纳入港股通标的证券名单，充分彰显了资本市场对本公司创新实力与长期发展潜力的高度认可。本次纳入有望进一步丰富本公司投资者结构，提升本公司股票在二级市场的流动性。展望未来，基石药业将持续推动核心资产的全球开发，凭借高效的管线推进与商业化布局，夯实核心竞争力，为广大投资者创造长期、可持续的价值回报。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260907/32361373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["FLHK","02616","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195344843","title":"基石药业-B（02616.HK）将于2026年9月7日正式纳入港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=1195344843","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195344843?lang=zh_cn&edition=full","pubTime":"2026-09-07 08:16","pubTimestamp":1788740174,"startTime":"0","endTime":"0","summary":"2026年9月7日，基石药业-B公告称，其在香港联合交易所上市的股份已获纳入港股通标的证券名单，生效日期同为2026年9月7日。公告显示，公司管理层认为，被纳入港股通有望丰富投资者结构，并提升公司股票在二级市场的流动性。基石药业成立于2015年底，专注于肿瘤、免疫与炎症等领域的创新药物研发。基石药业提醒投资者在买卖公司股票时保持审慎，并遵循专业建议。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665360401","title":"高盛、杰富瑞齐声看好基石药业-B(02616.HK)：CS2009疗效信号持续增强 关键催化剂有望密集兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2665360401","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665360401?lang=zh_cn&edition=full","pubTime":"2026-09-07 08:02","pubTimestamp":1788739364,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127798182","title":"基石药业-B更新8月股份变动月报表，股本小幅增加46,920股","url":"https://stock-news.laohu8.com/highlight/detail?id=1127798182","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127798182?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:45","pubTimestamp":1788511524,"startTime":"0","endTime":"0","summary":"基石药业-B于2026年9月4日公告披露截至2026年8月31日的股份变动月报表。报告显示，公司法定/注册股本未发生变化，仍为2,000,000,000股，面值每股0.0001美元，对应注册股本总额200,000美元。截至8月底，公司已发行股份总数增至1,596,323,572股。基石药业-B确认符合香港联交所主板上市规则所规定的公众持股量要求，并承诺遵守所有适用的法律法规。公告由公司董事李伟签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664893277","title":"港股异动 | 基石药业-B(02616)早盘涨超4% 普拉替尼纳入医保后销售放量 上半年收入激增超3倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2664893277","media":"智通财经","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664893277?lang=zh_cn&edition=full","pubTime":"2026-09-02 11:42","pubTimestamp":1788320549,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B早盘涨超4%。消息面上，基石药业发布中期业绩，上半年收入2.05亿元人民币，同比增加314.75%。其中药品销售收入1.83亿元，主要来自普拉替尼、阿伐替尼和舒格利单抗。普拉替尼自2026年1月纳入国家医保目录后，截至2026年7月院内销售额同比增长近500%，成为收入增长的主要驱动力。恒生综合指数变动将于9月4日收市后实施并于9月7日起生效，届时沪深交易所会相应调整港股通可投资标的范围。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1574","BK1161","BK4585","BK4588","KCAI","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662704651","title":"基石药业-B(02616)发布中期业绩，收入2.05亿元 同比大幅增长314.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662704651","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662704651?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:39","pubTimestamp":1787830749,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布截至2026年6月30日止6个月的中期业绩，该集团取得收入人民币2.05亿元，同比增加314.75%;期内亏损2.52亿元，同比减少6.62%;每股亏损0.17元。公告称，收入包括药品销售1.83亿元、授权费收入690万元及舒格利单抗特许权使用费收入 1500万元。收入的大幅增长主要由药品的销售额显著增加所带动，此乃由于该药物自2026年1月起成功纳入国家医保药品目录，从而带动销量显著上升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109600233","title":"基石药业-B(02616)2026年上半年营收2.05亿元，经调整净亏损2.31亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109600233","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109600233?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:36","pubTimestamp":1787830614,"startTime":"0","endTime":"0","summary":"基石药业-B发布的财报显示，2026年上半年实现营收2.05亿元，较上年同期的0.49亿元同比增长315.20%。经调整后的净亏损为2.31亿元，相比去年同期的2.65亿元亏损缩小约0.34亿元。成本方面，研发开支为2.06亿元，同比上升约95.30%，主要系CS2009等相关临床试验及早期研发投入加大。行政开支为0.51亿元，同比增长17.90%，主要由于人员成本增加所致。财报显示，在本期2.05亿元营收中，药品销售贡献1.83亿元，授权费收入约0.07亿元，特许权使用费约0.15亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"基石药业-B(02616)2026年上半年营收2.05亿元，经调整净亏损2.31亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":-0.104},{"period":"1month","weight":-0.2103},{"period":"3month","weight":0.0364},{"period":"6month","weight":-0.5351},{"period":"1year","weight":-0.3116},{"period":"ytd","weight":-0.1091}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":-0.0245},{"period":"3month","weight":-0.0203},{"period":"6month","weight":-0.0802},{"period":"1year","weight":-0.0713},{"period":"ytd","weight":-0.0612}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"基石药业是一家主要从事肿瘤、自身免疫和炎症及其他关键疾病领域药物研发及销售的投资控股公司。该公司通过子公司主要从事生物制药产品的研发、药品的销售及提供其知识产权（IP）授权或商业化授权。该公司产品主要包括精准治疗药物“泰吉华”（阿伐替尼）及“普吉华”（普拉替尼）、以及“择捷美”（舒格利单抗）等。该公司还从事肿瘤免疫药物的开发及商业化。该公司主要在中国国内市场、以及中欧、东欧和瑞士等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.050688},{"month":2,"riseRate":0.428571,"avgChangeRate":0.069097},{"month":3,"riseRate":0.25,"avgChangeRate":-0.053883},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.031371},{"month":5,"riseRate":0.428571,"avgChangeRate":0.066954},{"month":6,"riseRate":0.625,"avgChangeRate":0.030763},{"month":7,"riseRate":0.5,"avgChangeRate":0.038991},{"month":8,"riseRate":0.5,"avgChangeRate":0.110606},{"month":9,"riseRate":0.5,"avgChangeRate":-0.058868},{"month":10,"riseRate":0.375,"avgChangeRate":-0.036201},{"month":11,"riseRate":0.571429,"avgChangeRate":0.010396},{"month":12,"riseRate":0.428571,"avgChangeRate":0.004524}],"exchange":"SEHK","name":"基石药业-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"基石药业-B,02616,基石药业-B股票,基石药业-B股票老虎,基石药业-B股票老虎国际,基石药业-B行情,基石药业-B股票行情,基石药业-B股价,基石药业-B股市,基石药业-B股票价格,基石药业-B股票交易,基石药业-B股票购买,基石药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}